Last mentioned: Mar 15, 2026
Eventide Rebalancing
Eventide Asset Management reports a reduced but significant stake of $83.65 million in Collegium.
Institutional Reduction
Integrated Quantitative Investments LLC reduces its stock position in COLL.
Truist Analysis
Truist Securities highlights momentum for Jornay PM and a robust pain portfolio.
BDSI Acquisition
Collegium completes the acquisition of BioDelivery Sciences International, adding Belbuca to its portfolio.
Eventide Asset Management LLC has reduced its equity position in Collegium Pharmaceutical, Inc. (COLL), though it maintains a significant $83.65 million stake. This institutional shift comes as the specialty pharmaceutical firm navigates a shifting landscape for chronic pain management and expands into neurology.
Eventide Asset Management LLC has reduced its position in Collegium Pharmaceutical, Inc. (COLL), though it maintains a significant remaining stake valued at $83.65 million. This institutional shift comes as Collegium continues to integrate recent acquisitions and navigate the complex regulatory landscape of the specialty pain management market.
Eventide Asset Management LLC has reduced its position in Collegium Pharmaceutical, Inc. (COLL), though it maintains a significant $83.65 million stake. This institutional rebalancing occurs as the specialty pharmaceutical sector faces evolving regulatory scrutiny and a transition toward non-opioid pain management solutions.
CRA International (CRAI) and Collegium Pharmaceutical (COLL) both reported strong Q4 2025 results, highlighting a robust environment for specialized consulting and chronic pain management. While CRAI benefited from record headcount and high utilization in antitrust and litigation, Collegium demonstrated the continued commercial durability of its Belbuca and Xtampza ER franchises.
Collegium Pharmaceutical's Q4 2025 results showcase a successful strategic shift toward diversification, led by the ADHD treatment Jornay PM. Simultaneously, CRA International’s earnings highlight a surging demand for specialized life sciences consulting amid a complex regulatory landscape.